For the Inventor, By the Inventor

Enter assignee name

Askat Inc.

USPTO Granted Patents = 14

CIPO Patents = 5

EPO Patents = 9

Forward Citations = 26

Loading Chart...

Loading Chart...

21 inventors (with patents filed for the assignee):

Takako Okumura (11 out of 13 patents)

Shinichi Koizumi (7 out of 14 patents)

Yukinori Take (5 out of 7 patents)

4. Kazuhiko Nonomura (4 out of 7 patents)

5. Yoshiyuki Okumura (3 out of 18 patents)

6. Naoko Ohtani (2 out of 5 patents)

7. Fumitaka Kamachi (2 out of 2 patents)

8. Tze Mun Loo (2 out of 4 patents)

9. Yukari Inami (2 out of 2 patents)

10. Mark Manfredi (1 out of 1 patent)

11. Jeffrey Ecsedy (1 out of 1 patent)

12. Atsushi Nagahisa (1 out of 1 patent)

13. Masaki Sudo (1 out of 7 patents)

14. Alfredo C Castro (1 out of 114 patents)

15. Toyoharu Numata (1 out of 9 patents)

14 patents: Sort by Forward Citations

1. 12295962 - Polymorphic compounds and uses thereof (2025-05-13),

2. 11964963 - Stable salt and crystal forms of 2-[3-({1-[2-(dimethylamino)ethyl]-2-(2,2-dimethylpropyl)-1H-1,3-benzodiazol-5-yl}sulfonyl)azetidin-1-yl]ethan-1-ol (2024-04-23),

3. 11840530 - Selective EP4 receptor antagonistic substance for treatment of cancer (2023-12-12),

4. 11555023 - Process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids (2023-01-17),

5. 10973834 - EP4 inhibitors and use thereof (2021-04-13),

6. 10947235 - Selective EP4 receptor antagonistic substance for treatment of cancer (2021-03-16),

7. 10786490 - Use of EP4 receptor antagonists in the treatment of cartilage disease (2020-09-29),

8. 10611761 - Selective EP4 receptor antagonistic substance for treatment of cancer (2020-04-07),

9. 10583129 - Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer (2020-03-10),

10. 10391086 - Use of EP4 receptor antagonists in the treatment of cartilage disease (2019-08-27),

11. 10342785 - Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer (2019-07-09),

12. 9688674 - Selective EP4 receptor antagonistic substance for treatment of cancer (2017-06-27),

13. 9561210 - Therapeutic agent for ocular disease (2017-02-07),

14. 9447066 - Salts and crystal forms (2016-09-20),

AskAt Inc. is a leading technology company specializing in the development of advanced software solutions. With a focus on innovation, our expert team of engineers and researchers strive to deliver cutting-edge products that enhance productivity and efficiency across various industries. Our solutions range from artificial intelligence and machine learning algorithms to data analytics and cloud computing. At AskAt Inc., we are committed to providing exceptional software solutions that empower businesses and individuals to achieve their goals.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

14 Patents

#53 in Nagoya

#3,493 in Japan

#40,937 in the World

Askat Inc.

Forward Citations = 26

21 inventors:

Takako Okumura (11 out of 13 patents)

Shinichi Koizumi (7 out of 14 patents)

Yukinori Take (5 out of 7 patents)

4. Kazuhiko Nonomura (4 out of 7 patents)

5. Yoshiyuki Okumura (3 out of 18 patents)

Please report any incorrect information to support@idiyas.com

Loading…